MAPT and Alzheimer disease: Until Tau imaging can be investigated in vivo [23], [24], we conclude that the temporal progression of the CSF Aß42 biomarker and the spatial and temporal evolution of extracellular amyloid pathology are more directly correlated with our preclinical AD data than that of the later temporal change of the CSF Tau biomarker and the spatial and temporal evolution of the intraneuronal neurofibrillary pathology.